Table 7.51Study withdrawals

Withdrawal outcomesReferenceInterventionAssessment timeOutcome/effect size
Hand
Number of withdrawals1 RCT (Rothacker et al. 1994) (N=50)Trolamine salicylate vs placeboDuring treatmentN=1 (trolamine)
N=0 (placebo)
Number of withdrawals due to AEs1 RCT (Rothacker et al. 1994) (N=50)Trolamine salicylate vs placeboDuring treatmentBoth: N=0
Number of withdrawals1 RCT (Rothacker et al. 1998) (N=86)Trolamine salicylate vs placeboDuring treatmentN=2 (trolamine)
N=3 (placebo)
Mixed (Knee and/or hip)
Number of withdrawalsOne RCT (Shackel et al. 1997) (N=116)Copper-salicylate vs placeboDuring 4 weeks treatment26% (copper-salicylate)
17% (placebo)
Withdrawals due to AEsOne RCT (Shackel et al. 1997) (N=116)Copper-salicylate vs placeboDuring 4 weeks treatment17% (copper-salicylate) 1.7% (placebo)
Withdrawals due to lack of efficacyOne RCT (Shackel et al. 1997) (N=116)Copper-salicylate vs placeboDuring 4 weeks treatment5.2 (copper-salicylate)
3.4 (placebo)

From: 7, Pharmacological management of osteoarthritis

Cover of Osteoarthritis
Osteoarthritis: National Clinical Guideline for Care and Management in Adults.
NICE Clinical Guidelines, No. 59.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.